Validity and reliability of a Persian version of the self-evaluation of negative symptoms (SNS)

Shahrzad Mazhari 1,2, Anahita Karamooz 2*, Mahin Eslami Shahrbabaki 2, Farzaneh Jahanbakhsh 2 and Sonia Dollfus 3

Abstract

Aim: The Self-evaluation of Negative Symptoms (SNS) has been developed to allow schizophrenia patients to evaluate themselves in five dimensions of negative symptoms. The present study aimed to examine psychometric properties of the Persian version of SNS.

Methods: A group of 50 patients with schizophrenia and a group of 50 healthy controls received the Persian-SNS. Severity of negative symptoms were evaluated by the Scale for Assessment of Negative symptoms (SANS) and the Brief Psychiatric Rating Scale (BPRS).

Results: The results showed that the Cronbach’s alpha for the Persian SNS was 0.95. The Persian-SNS and its subscales showed significant positive correlations with the total SANS score and SANS subscales as well as BPRS negative subscale, thus confirming the validity of the scale. Finally, the Persian-SNS showed the ability to discriminate patients with schizophrenia from healthy controls.

Conclusion: The acceptable properties of the Persian version of SNS demonstrated that it is a practical tool for screening negative symptoms in Persian-speaking schizophrenia patients.

Keywords: Negative symptoms, Persian, Psychometrics, Schizophrenia, SNS

Introduction

Negative symptoms in patients with schizophrenia indicate the loss of certain behaviors or normal functioning, and are found at any stage of the disorder including: prodromal, acute, and residual phases. Negative symptoms usually persist even with improvements in positive symptoms, leading to poorer clinical outcome and quality of life [1].

Studies have reported severe negative symptoms in 26–36% of patients with schizophrenia [2]. Despite their high prevalence, recognizing negative symptoms is difficult due to secondary negative symptoms, which are caused by depression, antipsychotic adverse effects, social deprivation, or substance abuse [3, 4]. In recent studies, different standardized tools such as Brief Negative Symptom Scale (BNSS) and Clinical Assessment Interview for Negative Symptoms (CAINS) have been presented for a more effective treatment of negative symptoms [5, 6]. These instruments evaluate the severity of negative symptoms based on the evaluation of the observer, but not on the patient’s self-evaluation [7]. In fact, researchers believe that self-reporting complements objective evaluations of negative symptoms in schizophrenia, since patients are able to accurately express negative symptoms [7–10]. Moreover, patients’ self-evaluation is important because it allows them to evaluate their overall performance and participate in the process of examining and analyzing their symptoms,
which in turn encourages them to participate more in the treatment process [11]. Finally, self-evaluation helps to identify negative symptoms at an early stage of the disorder [11].

Until now, a number of scales have been developed to assess the subjective experience of negative symptoms in patients with schizophrenia, including Subjective Experience of Deficits in Schizophrenia (SEDS) [12], Subjective Deficit Syndrome Scale [13], Subjective Experience of Negative Symptoms (SENS) [14], and Motivation and Pleasure Scale Self-Report (MAPSR). These scales have some limitations. For instance, the older scales are not self-assessment and the MAPSR fails to examine all the five dimensions [15].

Recently, Self-evaluation of Negative Symptoms (SNS) was developed by Dollfus et al. (2016) for schizophrenia patients and it has adequate psychometric properties of reliability and validity [11]. SNS has several advantages: it is short with 20 easily-understandable sentences and there are three options for each sentence which allows for a quick self-evaluation in only 5 minutes. Finally, SNS examines all the five dimensions of negative symptoms: motivation, asociaity, alogia, anhedonia, and diminished emotional range [11].

To date, SNS has been translated into different languages including French [16], Lithuanian [17, 18], Spanish [19], Arabic [20] and Polish [21], and it has been validated with acceptable reliability and validity values. Persian, which is the official language of Iran, Afghanistan, and Tajikistan, is one of the most important languages of the Middle East and Central Asia. Over 110 million people speak Persian around the world and it is the 13th most spoken language in the world.

The aim of this study was to examine the reliability and validity of the Persian version of SNS in a group of Persian-speaking schizophrenia patients. It should be emphasized that all the methods were carried out in accordance with relevant guidelines and regulations.

**Methods**

**Participants**

A group of 50 Persian-speaking hospitalized schizophrenia patients (34 males) participated in the study. All the patients met the DSM-5 criteria for a lifetime diagnosis of schizophrenia based on diagnostic interview by two psychiatrists, and were receiving antipsychotic medications. The control group consisted of 50 healthy controls (34 males) with no personal or family history of psychotic illnesses. Exclusion criteria for both groups included history of head trauma, neurological disorders, and current substance dependency (within the past month). A written informed consent was obtained from all the participants as well as legally authorized representatives of human participants in the manuscript as Schizophrenia patients. The study was approved by the Ethics Committee of Kerman University of Medical Sciences (FR-622-28).

**Persian adaptation procedure**

The standard forward-backward method was used for translation of SNS to Persian [22]. First, SNS was translated into Persian by two Persian-speaking psychiatrists. Second, these Persian versions were back translated into French by two independent bilingual experts who were blind to the original French version. In cases of incompatibility, an attempt was made to consider the underlying concepts rather than the literal translation. In the next step, the back-translated version was emailed to the original author (S. Dollfus). Finally, the back-translated version was amended and approved by Dr. Dollfus.

**Symptom assessment**

SNS is self-evaluation of 20 items, evaluating the five areas of negative symptoms, giving each item a score of either 0 (strongly agree), 1 (somewhat agree), or 2 (strongly disagree). The total score ranges from 0 to 40, and the higher the score, the more severe the negative symptoms [16].

The Brief Psychiatric Rating Scale (BPRS) is a clinician-rated measure that assesses psychiatric symptoms. BPRS has 18 items which are rated on a seven-point Likert scale ranging from 1 (no sign) to 7 (severe). Higher scores indicate more severe psychopathology. Two sub scores can be determined for the positive (hallucinations, delusions, etc.) and negative (motor retardation, blunted affect, etc.) symptoms [18].

The Scale of Assessment of Negative Symptoms (SANS) has 25 items and measures the severity of negative symptoms in five subscales. Each item is rated from zero to five, and a higher score indicates a higher intensity of negative symptoms [19].

The Calgary Depression Scale for Schizophrenia (CDSS) is a nine-item semi-structured interview for assessing depressive symptoms in schizophrenia patients. Every item is rated on a four-point scale ranging from 0 (no symptom) to 3 (severe symptom) [23].

**Statistical analyses**

Demographic and clinical data were compared between the two groups by using χ²-test for categorical variables and independent t-tests for continuous variables. Internal consistency was assessed by Cronbach’s alpha coefficient. Convergent validity was calculated using the Pearson correlation coefficient between the SNS total score and the BPRS negative score, and between the SNS subscores and the corresponding subscores of SANS. Sensitivity and specificity were calculated using...
receiver-operator curve (ROC), with all the patients coded as ‘cases’ and all the controls as ‘non-cases’.

Results

Table 1 shows demographic and clinical characteristics of Persian study participants, who live in Iran. The two groups were well matched in terms of age, gender, and years of education. Schizophrenia patients had significantly higher SNS sub-scores as well as SANS and BPRS scores than the controls (Table 1).

Reliability

Internal consistency for the 20 items of SNS was calculated using Cronbach’s alpha coefficient. The results showed excellent consistency with $\alpha_c = 0.95$. Moreover, the inter-correlations between the five SNS sub-scores were significant (moderate to strong) in patients with schizophrenia (Table 2).

Validity

There were positive significant correlations between the SNS sub-scores and the SANS sub-scores, and between the SNS total score and BPRS negative sub-scores in schizophrenia patients (Table 3). However, there were not significant correlations between the SNS total score and the BPRS positive sub-score, or between the SNS total score and CDSS score ($r = 0.09$).

In this section, a ROC analysis was used to examine the contribution of the SNS total score to distinguish patients with schizophrenia from healthy controls. Herein, the area under ROC was 0.97 with 95% confidence interval (CI) = 0.94–1.0, $p \leq 0.001$, sensitivity was 0.98, and specificity was 0.84 with the cut-off value of 7.5. As shown in Fig. 1, the results emphasize on the significant ability of the SNS total score for discriminating between schizophrenia patients and controls. Different thresholds according to sensitivity and specificity are shown in Table 4.

Table 1 Demographic and clinical characteristics of Persian study participants, who live in Iran (mean ± SD)

| Characteristic            | Patients $n = 50$ | Controls $n = 50$ | p value |
|---------------------------|------------------|------------------|---------|
| Age (years)               | 39.5 ± 11.1      | 38.2 ± 11.2      | 0.90    |
| Education (years)         | 9.8 ± 2.4        | 11.6 ± 2.2       | 0.07    |
| Sex- N (% males)$^a$      | 34 (68.0%)       | 33 (66.0%)       | 0.83    |
| SNS                       |                  |                  |         |
| Social withdrawal         | 5.9 ± 2.7        | 0.86 ± 1.3       | < 0.0001|
| Decreased emotional range | 5.7 ± 2.5        | 0.69 ± 1.1       | < 0.0001|
| Alogia                    | 5.8 ± 2.5        | 0.53 ± 0.9       | < 0.0001|
| Avolition                 | 6.1 ± 2.2        | 0.94 ± 1.2       | < 0.0001|
| Anhedonia                 | 5.1 ± 2.5        | 0.41 ± 0.6       | < 0.0001|
| Total score               | 28.4 ± 11.0      | 3.4 ± 3.5        | < 0.0001|
| SANS                      |                  |                  |         |
| Total score               | 71.1 ± 20.1      | 9.6 ± 8.9        | < 0.0001|
| BPRS                      |                  |                  |         |
| Negative symptoms         | 8.1 ± 2.4        | 2.4 ± 0.8        | < 0.0001|
| Total score               | 40.1 ± 5.7       | 18.6 ± 3.0       | < 0.0001|
| CDSS                      |                  |                  |         |
| Total score               | 6.2 ± 3.5        | –                | –       |
| CDSS score > 8 (%)        | 20               | –                | –       |
| Length of illness (years) | 9.4 ± 6.6        | –                | –       |
| Age at onset (years)      | 19.3 ± 5.7       | –                | –       |
| Mean chlorpromazine equivalent (mg) | 468.7 ± 241.6 |         |         |

SNS Self-evaluation of Negative symptoms, SANS Scale for the Assessment of Negative Symptoms, BPRS Brief Psychiatric Rating Scale, CDSS Calgary Depression Syndrome Scale, $^a$: $\chi^2$-test

Table 2 Inter-correlations between the SNS sub-scores in schizophrenia patients

| SNS sub-scores     | Alogia | Avolition | Anhedonia | Social withdrawal | Diminished emotional range |
|--------------------|--------|-----------|-----------|-------------------|---------------------------|
| Alogia             | 1      | 0.55**    | 0.67**    | 0.46**            | 0.76**                    |
| Avolition          | 0.55** | 1         | 0.75**    | 0.50**            | 0.67**                    |
| Anhedonia          | 0.67** | 0.75**    | 1         | 0.73**            | 0.73**                    |
| Social withdrawal  | 0.46** | 0.58**    | 0.73**    | 1                 | 0.64**                    |
| Diminished emotional range | 0.75** | 0.67**    | 0.73**    | 0.64**            | 1                         |

** $p < 0.01$
Discussion
Self-evaluation tools are important in order to empower schizophrenia patients to evaluate themselves in different dimensions of negative symptoms, and research and clinical works with an emphasis on negative symptoms of schizophrenia play an important role in this process. It seems necessary to introduce standard instruments with satisfactory psychometric features to countries and ethnicities with different languages. It should be mentioned that no self-evaluation tool for negative symptoms used in schizophrenia studies has been translated and validated into Persian language. In order to investigate the self-assessment of schizophrenia patients in the five negative domains of avolition, anhedonia, alogia, social withdrawal, and diminished emotional range, SNS can be considered as a valuable self-evaluation tool.

Overall, the results of this study showed that the Persian-SNS has high internal consistency, good convergent and discriminant validities, and a strong ability to distinguish patients with schizophrenia from healthy controls.

The results showed that the internal consistency of the Persian-SNS was good and similar to those of the French [16], Spanish [19], Arabic [20], and Polish [24] versions.

Similar to previous studies, there were significant correlations between the Persian-SNS subscales and the total score and subscales of SANS and BPRS-negative scale. The highest correlations were found between the total score of SNS with total score of SANS (r = 0.89) and asociality scales (r = 0.83). Similar results were found in the original paper (10) (Dolfus et al., 2016) and in another French sample [16]. This finding indicates the good convergent validity of the Persian-SNS and suggests that it is a useful tool for assessing negative symptoms in Persian-speaking schizophrenia patients.

In agreement with the Dolfus et al. study (2019) [25], the results of ROC analysis showed that the total score of Persian SNS differentiated patients with schizophrenia from controls, with sensitivity and specificity of 0.98 and 0.84, respectively. This result indicates that the Persian SNS is a valuable tool for discriminating between patients and controls based on negative symptoms.

There are some limitations to this study. First, test-retest reliability was not examined in this study, future research is required for assessing the reliability of the Persian-SNS over time. Second, relatively small number of patients participated in the study; however, this

Table 3 Intercorrelations between the SNS sub-scores and SANS in schizophrenia patients

|                      | Total score | Alogia | Avolition | Anhedonia | Social withdrawal | Diminished emotional range |
|----------------------|-------------|--------|-----------|-----------|-------------------|---------------------------|
| BPRS-negative        | 0.70**      |        |           |           |                   |                           |
| SANS                 |             | 0.89** |           |           |                   |                           |
| Total score          |             |        | 0.78**    |           |                   |                           |
| Alogia               |             |        |           | 0.76**    |                   |                           |
| Avolition            |             |        |           |           | 0.83**            |                           |
| Anhedonia-Asociality|             |        |           |           |                   | 0.70**                    |
| Affect               |             |        |           |           |                   |                           |

** p < 0.01, SNS: Self-evaluation of Negative symptoms, SANS: Scale for Assessment of Negative Symptoms, BPRS: Brief Psychiatric Rating Scale

Table 4 Sensitivity and specificity of SNS for different threshold values

| Threshold | Sensitivity | Specificity |
|-----------|-------------|-------------|
| 4.5       | 0.98        | 0.64        |
| 5.5       | 0.98        | 0.68        |
| 6.5       | 0.98        | 0.80        |
| 7.5       | 0.98        | 0.84        |
| 8.5       | 0.96        | 0.88        |
| 9.5       | 0.94        | 0.90        |
| 10.5      | 0.94        | 0.96        |

Fig. 1 Receiver-operator curve for discrimination between schizophrenia patients and healthy controls
number is similar to that used by the original study for validation of the scale (49 patients).

In conclusion, the Persian SNS showed satisfactory reliability and validity, suggesting that it is a useful tool for evaluation of negative symptoms in clinical practice and research studies of the Persian-speaking people.

Acknowledgements
This research was supported by the Neuroscience Research Center, Kerman University of Medical Sciences. The authors would like to thank all the patients who participated in this study.

Authors’ contributions
S.M. designed the study, drafted and revised the manuscript. A.K. and M.E.S. participated in interviews with schizophrenia patients and collected data. F.J. analyzed the data, and S.D. provided valuable research guidance. All the authors read and approved the final manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The ethical approval was obtained from Kerman University of Medical Sciences (IR622-28). The informed consent was provided by all the participants. The study was conducted in accordance with the relevant guidelines.

Consent for publication
Not applicable.

Competing interests
The authors have no competing interest to declare.

Author details
1Neuroscience Research Center, Institute of Neuropsycharmacology, Kerman University of Medical Sciences, Kerman, Iran. 2Department of Psychiatry, Shahid-Beheshti Hospital, Kerman University of Medical Sciences, P.O. Box: 76175-113, Kerman, Iran. 3Department of Psychiatry, Center Hospitalier Universitaire, 14000 Caen, France.

Received: 3 April 2021 Accepted: 6 October 2021
Published online: 20 October 2021

References
1. Correll CU, Schoeler NR. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat. 2020;16:519–34. https://doi.org/10.2147/NDDT.S225643.
2. Blanchard JJ, Horan WP, Collins LM. Examining the latent structure of negative symptoms: is there a distinct subtype of negative symptom schizophrenia? Schizophr Res. 2005;77(2):151–65. https://doi.org/10.1016/j.schres.2005.03.022.
3. Barnes T, McPhillips M. How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia. Int Clin Psychopharmacol. 1995;10:115–22.
4. Dolfus S, Pettit M. Negative symptoms in schizophrenia: their evolution during an acute phase. Schizophr Res. 1995;17(2):187–94. https://doi.org/10.1016/0920-9964(94)90087-O.
5. Strauss GP, Keller WR, Buchanan RW, Gold JM, Fischer BA, McMahon RP, et al. Next-generation negative symptom assessment for clinical trials: validation of the brief negative symptom scale. Schizophr Res. 2012;142(1–3):88–92. https://doi.org/10.1016/j.schres.2012.10.012.
6. Kring AM, Gur RE, Blanchard JJ, Horan WP, Reise SP. The clinical assessment interview for negative symptoms (CAINS): final development and validation. Am J Psychiat. 2013;170(2):165–72. https://doi.org/10.1176/appi.ajp.2012.12010109.
7. Selten JP, Wiersma D, van den Bosch RJ. Clinical predictors of discrepancy between self-ratings and examiner ratings for negative symptoms. Compr Psychiatry. 2000;41(3):191–6. https://doi.org/10.1053/cmpy.2000.09047-6.
8. Hamner EK, Schneider JK, Potosky M, Casebeer MA. Validity of self-administered symptom scales in clients with schizophrenia and schizoaffective disorders. Schizophr Res. 1996;19(2–3):213–9. https://doi.org/10.1016/0920-9964(95)00100-X.
9. Fleischhacker WW, Rabinowitz J, Kemmler G, Eerdekens M, Mehnert A. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry. 2005;187(2):131–6. https://doi.org/10.1192/bjp.187.2.131.
10. Ohata H, Yotsutomo K, Taira M, Kochi Y, Hashimoto T. Reliability and validity of a Brief Self-rated Scale of Health condition with a cute S schizophrenia. Psychiatry Clin Neurosci. 2014;68(1):70–7. https://doi.org/10.1111/pcn.12105.
11. Dolfus S, Mach C, Morello R. Self-evaluation of negative symptoms: a novel tool to assess negative symptoms. Schizophr Bull. 2016;42(3):571–8. https://doi.org/10.1093/scan/nsv016.
12. Liddle PF, Barnes TR. The subjective experience of deficits in schizophrenia. Compr Psychiatry. 1988;29(2):157–64. https://doi.org/10.1016/0010-448X(88)90099-0.
13. Jaeger J, Bitter I, Czobor P, Volavka J. The measurement of subjective experience in schizophrenia: the subjective deficit syndrome scale. Compr Psychiatry. 1990;31(3):216–26. https://doi.org/10.1016/0010-448X(90)90005-D.
14. Selten JP, Siiben NE, van den Bosch RJ, Onnico-Visser J, Warmerdam H. The subjective experience of negative symptoms: a self-rating scale. Compr Psychiatry. 1993;34(3):192–7. https://doi.org/10.1016/0010-448X(93)90047-8.
15. Leena K, Park SC, McCarthy JM, Couture SM, Bennett ME, Blanchard JJ. The motivation and pleasure scale-self-report (MAP-SP): reliability and validity of a self-report measure of negative symptoms. Compr Psychiatry. 2013;54(3):568–74. https://doi.org/10.1016/j.comppsych.2012.12.001.
16. Hervochon C, Bourgeois V, Rothamel M, Duboc J, Le Goff B, Quetsada P, et al. Validation of the French version of the self-evaluation of negative symptoms (SNS). L’encephale. 2017;44(6):512–6. https://doi.org/10.1016/j.encep.2017.10.002.
17. Montvidas J, Adomaitiene V, Leskauskas D, Dolfus S. Validation of the Lithuanian version of the self-evaluation of negative symptoms scale (SNS). Nord J Psychiatry. 2020;S5(1):1–5. https://doi.org/10.1080/08039488.2020.1862905.
18. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962; 10(3):799–812. https://doi.org/10.2466/pr0.1962.10.3.799.
19. Andreassen NC. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry. 1989;155(S7):49–52. https://doi.org/10.1192/bjo.155.5.549.
20. Rodríguez-Tenral JF, Perona-Garcén S, Dolfus S, Valdés-Díaz M, García-Martínez J, Ruiz-Veguilla M, et al. Spanish validation of the self-evaluation of negative symptoms scale SNS in an adolescent population. BMC Psychiatry. 2019;19(1):327. https://doi.org/10.1186/s12888-019-2314-1.
21. Haji A, Hallit S, Chamoun M, Sacre H, Obied S, Haddad C, et al. Validation of the Arabic version of the ‘self-evaluation of negative symptoms’ scale (SNS). BMC Psychiatry. 2020;20(1):1–8. https://doi.org/10.1186/s12888-020-02647-4.
22. Harkness JA, Van De Vijver FJ, Mohler PP. Cross-cultural survey methods: Wiley, Hoboken; 2002.
23. Addington D, Addington J, Schissel BA. A depression rating scale for schizoaffective disorders. Schizophr Res. 1990;3(4):247–51. https://doi.org/10.1016/0920-9964(90)90005-R.
24. Wójciak P, Górna K, Domowicz K, Jaracz K, Szpalik R, Michalak M, et al. Polish version of the self-evaluation of negative symptoms (SNS). Psychiatr Pol. 2019;53(3):551–9. https://doi.org/10.12740/PP/OnlineFirst/97352.
25. Dolfus S, Defouche C, Hervochon C, Mach C, Bourgeois V, Rothamel M, et al. Specificity and sensitivity of the self-assessment of negative symptoms (SNS) in patients with schizophrenia. Schizophr Res. 2019;211:51–5. https://doi.org/10.1016/j.schres.2019.07.012.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.